ZBIO

ETF / Mutual Fund
NASDAQ
ProShares UltraPro Short Nasdaq Biotechnology
Price Chart
Overview

About ZBIO

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and Fc?RIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

AUM
Volume
1.2M
Avg. Volume
1.6M
Expense Ratio

Top Holdings

Other
100.00%

Sector Allocation

Other100.00%

Country Allocation

Other100.00%

Fund Information

Exchange
NASDAQ
Sector
Risk & Correlation Analysis
Market Correlation
N/A
N/A
Volatility
N/A
Relative to market
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ZBIO.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ZBIO shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
AUM
Volume1.2M
Expense Ratio
Important Dates
Next Dividend
Next Earnings
November 12, 2024

PortfolioPilot Analysis

Get AI-powered insights on how ZBIO fits into your investment strategy and portfolio diversification.

Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025